Curis (NASDAQ:CRIS) Posts Earnings Results, Beats Expectations By $0.13 EPS

Curis (NASDAQ:CRIS) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.13, Zacks reports. The company had revenue of $3.18 million during the quarter, compared to analysts’ expectations of $2.86 million.

Curis Trading Down 10.3%

Shares of CRIS stock traded down $0.15 during trading on Friday, reaching $1.31. 233,192 shares of the company’s stock traded hands, compared to its average volume of 94,923. The firm’s 50-day moving average is $1.61 and its 200 day moving average is $1.85. The company has a market capitalization of $16.37 million, a P/E ratio of -0.27 and a beta of 3.88. Curis has a 1 year low of $1.02 and a 1 year high of $4.70.

Institutional Investors Weigh In On Curis

A hedge fund recently raised its stake in Curis stock. Maverick Capital Ltd. increased its stake in Curis, Inc. (NASDAQ:CRIS) by 7.8% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 681,381 shares of the biotechnology company’s stock after purchasing an additional 49,554 shares during the quarter. Maverick Capital Ltd. owned about 5.45% of Curis worth $1,472,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 29.97% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Curis in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $17.00.

Curis Company Profile

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.